Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Tocagen Inc (TOCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,167
  • Shares Outstanding, K 23,019
  • Annual Sales, $ 18,040 K
  • Annual Income, $ -48,960 K
  • 60-Month Beta 3.51
  • Price/Sales 14.05
  • Price/Cash Flow N/A
  • Price/Book 3.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.70
  • Number of Estimates 2
  • High Estimate -0.61
  • Low Estimate -0.79
  • Prior Year -0.65
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.86 +5.38%
on 03/11/19
12.00 -13.42%
on 03/05/19
-0.53 (-4.85%)
since 02/22/19
3-Month
6.47 +60.59%
on 12/24/18
12.00 -13.42%
on 03/05/19
+3.36 (+47.80%)
since 12/21/18
52-Week
6.47 +60.59%
on 12/24/18
15.80 -34.24%
on 10/02/18
-2.01 (-16.21%)
since 03/22/18

Most Recent Stories

More News
Implied Volatility Surging for Tocagen (TOCA) Stock Options

Investors need to pay close attention to Tocagen (TOCA) stock based on the movements in the options market lately.

TOCA : 10.39 (-5.63%)
Tocagen Reports Fourth Quarter and Full Year 2018 Financial and Business Results

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2018....

TOCA : 10.39 (-5.63%)
Tocagen to Report Fourth Quarter and Full Year Financial Results on Wednesday, February 27 and Present at Upcoming SVB Leerink Global Healthcare Conference

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced it will report its fourth quarter and full year 2018 financial results and business progress on Wednesday,...

TOCA : 10.39 (-5.63%)
Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN),...

ABUS : 3.53 (-4.59%)
AMRN : 17.51 (-6.66%)
RUN : 14.25 (-5.63%)
RTRX : 22.43 (-5.48%)
TOCA : 10.39 (-5.63%)
BSTC : 65.01 (-4.09%)
Tocagen Announces Pricing of Public Offering of Common Stock

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price to...

TOCA : 10.39 (-5.63%)
Tocagen Announces Proposed Public Offering of Common Stock

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All...

TOCA : 10.39 (-5.63%)
Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed Glioblastoma

Tocagen Inc. (Nasdaq: TOCA), a late clinical-stage, cancer-selective gene therapy company and NRG Oncology, a member of the National Cancer Institute's (NCI) National Clinical Trial Network (NCTN), today...

TOCA : 10.39 (-5.63%)
Investor Expectations to Drive Momentum within ANSYS, Nordic American Tankers, Woodward, GW Pharmaceuticals, CareTrust REIT, and TOCAGEN INC -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ANSYS, Inc. (NASDAQ:ANSS),...

NAT : 2.05 (-3.76%)
ANSS : 177.18 (-2.82%)
WWD : 93.16 (-4.13%)
GWPH : 168.83 (-4.07%)
CTRE : 23.43 (-1.80%)
TOCA : 10.39 (-5.63%)
Tocagen Appoints Lori Kunkel, M.D. as Acting Chief Medical Officer

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that Lori Kunkel, M.D. has been named acting chief medical officer, effective November 26, 2018. Asha...

TOCA : 10.39 (-5.63%)
Tocagen to Present Preclinical Data on Anti-PD-L1 Product Candidate Toca 521 at the 2018 Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced preclinical data on Toca 521, a retroviral replicating vector (RRV) expressing a single-chain variable...

TOCA : 10.39 (-5.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade TOCA with:

Business Summary

Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need....

See More

Key Turning Points

2nd Resistance Point 11.19
1st Resistance Point 10.79
Last Price 10.39
1st Support Level 10.19
2nd Support Level 9.99

See More

52-Week High 15.80
Fibonacci 61.8% 12.24
Fibonacci 50% 11.14
Last Price 10.39
Fibonacci 38.2% 10.03
52-Week Low 6.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar